B1680

Bradyzide di(trifluoroacetate) salt hydrate

≥98%

• Sinónimos: (S)-1-[4-(4-Benzhydrylthiosemicarbazido)-3-nitrobenzenesulfonyl]-pyrrolidine-2-carboxylic acid [2-[(2-dimethylaminoethyl)methylamino]ethyl] amide
• Fórmula empírica (notación de Hill): C₃₂H₄₂N₈O₅S₂ · 2C₂HF₃O₂ · xH₂O
• Peso molecular: 910.90 (anhydrous basis)
• UNSPSC Code: 41106200
• NACRES: NA.32
• MDL number: MFCD02684401
• Assay: ≥98%
• Form: solid

Propiedades

• Quality Segment: 100
• assay: ≥98%
• form: solid
• solubility: H₂O: >40 mg/mL
• storage temp.: −20°C

Descripción

Biochem/physiol Actions

Potent, orally active, non-peptide B₂ bradykinin receptor antagonist.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)